Hodgkin Lymphoma: A Comprehensive Overview

439 Pages·2015·8.033 MB·English

by  Andreas Engert, Anas Younes (eds.)

Hematologic Malignancies
Andreas Engert
Editors
Anas Younes
Hodgkin
Lymphoma
A Comprehensive Overview
Second Edition
Hematologic Malignancies
For further volumes:
http://www.springer.com/series/5416

Andreas Engert • A nas Younes
Editors
Hodgkin Lymphoma
A Comprehensive Overview

Second Edition
Editors
Andreas Engert Anas Younes
Universitätsklinikum Köln Klinik I für Memorial Sloan - Kettering
Innere Medizin Cancer Center
Köln New York
Germany USA
ISBN 978-3-319-12504-6 ISBN 978-3-319-12505-3 (eBook)
DOI 10.1007/978-3-319-12505-3
Springer Cham Heidelberg New York Dordrecht London
Library of Congress Control Number: 2014959423
© Springer International Publishing 2015
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or
part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of
illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way,
and transmission or information storage and retrieval, electronic adaptation, computer software,
or by similar or dissimilar methodology now known or hereafter developed. Exempted from this
legal reservation are brief excerpts in connection with reviews or scholarly analysis or material
supplied specifi cally for the purpose of being entered and executed on a computer system, for
exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is
permitted only under the provisions of the Copyright Law of the Publisher's location, in its
current version, and permission for use must always be obtained from Springer. Permissions for
use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable
to prosecution under the respective Copyright Law.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this
publication does not imply, even in the absence of a specifi c statement, that such names are
exempt from the relevant protective laws and regulations and therefore free for general use.
While the advice and information in this book are believed to be true and accurate at the date of
publication, neither the authors nor the editors nor the publisher can accept any legal responsibility
for any errors or omissions that may be made. The publisher makes no warranty, express or
implied, with respect to the material contained herein.
Printed on acid-free paper
Springer is part of Springer Science+Business Media (www.springer.com)
Pref ace
H odgkin lymphoma has become one of the most curable malignancies, both
in adult and pediatric patients. More than 80 % of all patients can be cured
with risk-adapted treatment including chemo- and radiotherapy. This prog-
ress is largely due to the development of multi-agent chemotherapy more
than 40 years ago and the improvements in radiotherapy. Since then, this
fascinating disease has been in the focus of scientifi c and clinical research.
Major recent achievements were the defi nite proof that Hodgkin lymphoma is
a true malignancy derived from “crippled” B-lymphocytes. Establishing
immortal cell lines from patients with end-stage disease initiated a variety of
different research activities that advanced our understanding of Hodgkin lym-
phoma pathophysiology, biology, and immunology, in addition to providing
an in vitro model for testing new therapies. The discovery of the CD30 anti-
gen that is expressed in high density on H-RS cells substantially improved the
prognostic precision. Monoclonal antibodies against this antigen were suc-
cessfully used for diagnostic immunophenotyping and were exploited thera-
peutically. After a number of unsuccessful clinical trials with unconjugated
antibody constructs or fully human monoclonal antibodies targeting CD30,
this strategy has come full circle with the advent of an anti-CD30 antibody
drug conjugate that has given remarkable responses in relapsed and refractory
Hodgkin lymphoma.
D ue to the very good prognosis and the young age of most patients
affected, Hodgkin lymphoma has also become a model to study long-term
effects of radio- and chemotherapy. Unfortunately, a substantial number of
patients die from treatment-related long-term toxicity. We must thus very
carefully balance our attempts to further improve disease control with the
need to keep the risk of long-term consequences as low as possible. In addi-
tion, there are a number of relevant physical and psychosocial issues that
need to be further exploited including the risk of infertility and fatigue.
Fortunately, after more than 20 years of standstill, we now experience the
development of new targeted treatment also for patients with Hodgkin lym-
phoma. This hopefully might result in more individualized and less toxic
treatments for our patients. The next decade will witness additional progress
relevant to exploiting the interaction between the malignant H-RS cells and
the immune cells in the microenvironment, which will likely result in further
refi nement of our treatment strategies.
v
vi Preface
This book should give you a comprehensive overview on the most relevant
biology, diagnostic and clinical aspects of Hodgkin lymphoma. We would
like to express our sincere gratitude to all those who have contributed to this
project.
Cologne , Germany Andreas Engert
New York , NY , USA Anas Younes
Contents
Part I Epidemiology and Pathogenesis
1 Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Sally L. Glaser, Ellen T. Chang, Christina A. Clarke,
and Theresa H. Keegan
2 The Role of Viruses in the Genesis of Hodgkin
Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Ruth F. Jarrett
3 Pathology and Molecular Pathology of Hodgkin
Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Andreas Rosenwald and Ralf Küppers
4 Microenvironment, Crosstalk, and Immune
Escape Mechanisms. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Lydia Visser, Anke van den Berg,
Sibrand Poppema, and Arjan Diepstra
5 What Will We Learn from Genomics and Proteomics
in Hodgkin Lymphoma? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
Christian Steidl and Randy D. Gascoyne
Part II Diagnosis and First-Line Treatment
6 Clinical Evaluation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
Jim Armitage and Christian Gisselbrecht
7 Functional Imaging in Hodgkin Lymphoma. . . . . . . . . . . . . . 107
Andrea Gallamini, Martin Hutchings, and Anna Borra
8 Prognostic Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
Lena Specht and Dirk Hasenclever
9 Principles of Radiation Therapy for Hodgkin
Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
Joachim Yahalom and Richard T. Hoppe
10 Principles of Chemotherapy in Hodgkin Lymphoma. . . . . . . 177
Peter Johnson and David Straus
vii
viii Contents
11 Treatment of Early Favorable Hodgkin Lymphoma . . . . . . . 201
Pieternella Lugtenburg and Anton Hagenbeek
12 Treatment of Early Unfavorable HL . . . . . . . . . . . . . . . . . . . . 221
John M.M. Raemaekers and Andreas Engert
13 Treatment of Advanced-Stage Hodgkin Lymphoma . . . . . . . 235
Peter Borchmann, Massimo Federico, and Volker Diehl
Part III Special Clinical Situations
14 Pediatric Hodgkin Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . 253
Georgina W. Hall, Cindy L. Schwartz, Stephen Daw,
and Louis S. Constine
15 The Management of Older Patients with Hodgkin
Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 271
Boris Böll and Andrew M. Evens
16 Nodular Lymphocyte- Predominant Hodgkin Lymphoma. . . 287
Dennis A. Eichenauer and Michelle A. Fanale
17 The Management of Hodgkin Lymphoma During
Pregnancy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297
Veronika Bachanova and Joseph M. Connors
18 The Management of HIV-Hodgkin Lymphoma . . . . . . . . . . . 307
Michele Spina, Marcus Hentrich, and Umberto Tirelli
Part IV Relapsed and Refractory Disease
19 Relapsed and Refractory Hodgkin Lymphoma . . . . . . . . . . . 321
Bastian von Tresckow and Craig Moskowitz
20 Allogeneic Transplantation for Relapsed Hodgkin
Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 331
Anna Sureda and Stephen Mackinnon
21 Targeting CD30 in Patients with Hodgkin Lymphoma . . . . . 343
Anita Kumar, Stefano Pileri, Anas Younes,
and Andreas Engert
22 Other New Agents for Hodgkin Lymphoma . . . . . . . . . . . . . . 355
Alison J. Moskowitz and Anas Younes
Part V Survivorship
23 Quality of Life in Hodgkin Lymphoma . . . . . . . . . . . . . . . . . . 365
Teresa V. Halbsguth and Hans-Henning Flechtner
24 Second Malignancy Risk After Treatment of Hodgkin
Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375
David C. Hodgson and Flora E. van Leeuwen
Contents ix
25 Cardiovascular and Pulmonary Late Effects . . . . . . . . . . . . . 411
Berthe M.P. Aleman and David J. Cutter
26 Gonadal Dysfunction and Fertility Preservation
in Hodgkin Lymphoma Patients. . . . . . . . . . . . . . . . . . . . . . . . 427
Karolin Behringer and Michael von Wolff